市场调查报告书
商品编码
1119087
便秘治疗全球市场规模研究:按治疗剂、疾病类型(慢性特发性便秘、肠易激综合征便秘、阿片类药物引起的便秘)、分销渠道、地区预测 2022-2028Global Constipation Treatment Market Size study, by Therapeutic, Disease Type (Chronic idiopathic constipation, irritable bowel syndrome with constipation, and Opioid-induced constipation ), Distribution Channel, and Regional Forecasts 2022-2028 |
在 2022-2028 年的预测期内增长 9%。
便秘是持续数週或更长时间的不规则排便和硬便的持续状态。每周少于 3 次大便被认为是严重便秘,每周少于 1 次大便也是如此。便秘会导致排便疼痛、排便困难、排便不规则和肠道通道阻塞。急性便秘也会阻塞肠道并需要手术。腹胀、小腹不适、直肠出血、大便硬而肛裂、排便困难、胃痛、排便用力,都是便秘的征兆。因为它是一种特发性疾病,病因不明。市场受到主要因素的推动,例如最新药物和治疗方法的开发、老年人口的增加以及饮食习惯的改变。例如,根据美国疾病控制和预防中心 2021 年 11 月的数据,OIC 处方数量在 2019 年增加到 153,260,450 份,到 2020 年增加到 142,816,781 份。越来越多的服用阿片类药物的患者将推动对一种称为阿片类药物诱导的便秘( OIC )的有效治疗的需求,预计这将在整个预测期内推动便秘治疗市场。此外,从 2015 年到 2050 年,全球 60 岁及以上的人口将几乎翻一番,从 12% 增加到 22%。据世界卫生组织称,到 2030 年,地球上六分之一的人将超过 60 岁。此外,在医疗保健领域不断增长的投资将在未来几年提供重要的商机。然而,在 2022-2028 年的预测期内,对大多数非处方 (OTC) 药物的日益依赖正在阻碍市场增长。
全球便秘治疗市场研究考虑的主要地区包括亚太地区、北美、欧洲、拉丁美洲和世界其他地区。由于老年人口不断增加,亚太地区引领全球市场份额。然而,由于最新药物和治疗方法的开发,预计北美将成为增长最快的地区。
本报告中包括的主要市场进入者是:
本研究的目的是确定近年来各个细分市场和国家的市场规模,并预测未来八年的价值。本报告旨在捕捉所调查的每个地区和国家的行业的定性和定量方面。此外,它还提供了有关关键方面的详细信息,例如定义市场未来增长的驱动因素和挑战。此外,该报告还应纳入微观市场中可供利益相关者投资的可用机会,以及对竞争格局和主要参与者的应用产品的深入分析。市场的详细细分和子细分如下所述。
按药物
泻药
氯离子通道激活剂
外周作用的 Mu-阿片受体拮抗剂
其他
按疾病类型
慢性特发性便秘(CIC)
便秘型肠易激综合征(IBS-C)
阿片类药物引起的便秘 (OIC)
按销售渠道
医院药房
零售药店
网上药店
按地区
北美
美国
加拿大
欧洲
英国
德国
法国
西班牙
意大利
欧洲其他地区
亚太地区
中国
印度
日本
澳大利亚
韩国
其他亚太地区
拉丁美洲
巴西
墨西哥
世界其他地区
此外,本研究考虑的年份是:
实际年份 - 2018 年、2019 年、2020 年
2021 年基准年
预测期 - 2022-2028
本报告的目标受众是全球便秘治疗市场。
主要咨询公司和顾问
大公司、中型公司、中小企业
风险投资
增值经销商 (VAR)
第三方知识提供者
投资银行家
投资者
Global Constipation Treatment Market is valued at approximately USD XXX million in 2021 and is anticipated to grow with a healthy growth rate of more than 6.9% over the forecast period 2022-2028. Constipation is a constant condition that results in irregular bowel motions and hardened faeces that last for a few weeks or even longer. Having less than three stools per week is considered severe constipation, as is having fewer than one stool per week. It results in painful and stiff bowel movements, irregular stools, and difficult bowel passage. The intestines may become blocked because of acute constipation, necessitating surgery in some cases. Bloating, lower abdominal discomfort, rectal bleeding, anal fissures brought on by hard stools, inadequate evacuation, gastric pain, and straining during bowel movements are all signs of constipation. The causes of this disease are unknown because it is an idiopathic condition. The market is driven by the key factors such as development of Latest Drugs and Treatment Procedures and increasing Geriatric Population and Changing Dietary Habits. For instance, the number of OIC prescriptions grew by 153,260,450 in 2019 and 142,816,781 in 2020, according to the Centers for Disease Control and Prevention in November 2021. The increasing number of patients who take opioids necessitates effective treatment for conditions known as opioid-induced constipation (OIC), which is expected to drive the market for treatments for constipation throughout the projected period. furthermore, the global population aged 60 and up is nearly double from 12 percent to 22 percent from 2015 to 2050. Also, as per WHO, by 2030, 1 out of every 6 people on the planet will be 60 and above aged. Moreover, growing investment in healthcare creates lucrative opportunities in the upcoming years. However, increasing dependence on majority of over the counter (otc) drugs impedes the growth of the market over the forecast period of 2022-2028
The key regions considered for the global Constipation Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia Pacific is leading the global market share owing to rise in geriatric population. However, North America is expected to be the fastest growing region due to Development of Latest Drugs and Treatment Procedures in the region.
Major market players included in this report are:
Takeda Pharmaceutical Company Ltd.
Valeant Pharmaceuticals International Inc.
Ironwood Pharmaceuticals, Inc.
Pfizer Inc.
Salix Pharmaceuticals, Inc.
Abbott Laboratories
Bayer AG
Sanofi S.A.
Janssen Pharmaceutical Company
Cosmo Pharmaceuticals NV
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Application offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Therapeutics:
Laxatives
Chloride Channel Activators
Peripherally Acting Mu-Opioid Receptor Antagonists
Others
By Disease Type:
Chronic Idiopathic Constipation (CIC)
Irritable Bowel Syndrome with Constipation (IBS-C)
Opioid-Induced Constipation (OIC)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2018, 2019, 2020
Base year - 2021
Forecast period - 2022 to 2028
Target Audience of the Global Constipation Treatment Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
List of figures